dianosic

Dianosic is a biotechnology startup, founded in 2017, with the slogan "Smartly designed for you." The company aims to tackle challenges related to patient adherence to medication by providing an alternative to daily medication through a unique sustained intranasal drug delivery solution for respiratory and chronic central nervous system diseases. With a particular focus on chronic allergic rhinitis and chronic rhinosinusitis, Dianosic addresses the significant impact these conditions have on patients' quality of life. They collaborate closely with healthcare professionals, including physicians in otorhinolaryngology (ENT) and neurosurgery, to design solutions that improve physicians' experience and offer patients minimally invasive and non-surgical options. Dianosic's flagship product is ARIS, a unique platform leveraging proprietary drug-eluting, long-term resorbable polymer. This concept aims to deliver patient-centric "insert and forget" solutions, maximizing patient quality of life and addressing physicians' needs in terms of efficacy, safety, ease of use, and patient adherence to treatment. The company recently secured a €4.70M Seed Round investment on 06 February 2023 from investors including Bpifrance, Fondation Force, and WiSEED. Dianosic's headquarters is located in France, and for more information, they can be contacted via LinkedIn private message, email ([email protected]), or phone (+33 1 44 04 45 80). Overall, Dianosic presents a compelling solution for addressing medication adherence challenges in chronic diseases, and the recent investment indicates confidence from prominent investors in the viability of their approach.